—
C+
C+ The full Closelook — membership. Open the C+ overview

Roivant Sciences Ltd (ROIV) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Roivant Sciences Ltd

ROIV in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Roivant Sciences discovers, develops and aims to commercialise new medicines, mainly in autoimmune and cardiopulmonary disease. Its pipeline includes antibody and small-molecule candidates for conditions such as pulmonary hypertension, thyroid eye disease and several IgG-mediated autoimmune disorders, alongside lipid-nanoparticle and ligand-conjugate delivery platforms. It is based in London and operates as a clinical-stage biopharmaceutical company rather than a marketer of approved drugs.
Where it sits in the stack
Roivant carries no seat in our index; it belongs to the Healthcare sector of our universe, within the clinical-stage biotechnology sleeve, alongside other US-listed drug developers we track for score comparison rather than for any AI build-out layer.
Who it is priced against
Closelook's peer group places it with other scored Healthcare names in the US, including argenx, Regeneron, Vertex Pharmaceuticals and BeiGene; the market also often names Alnylam Pharmaceuticals as a comparable clinical-stage biotech.
Why Closelook tracks it
It carries a Closelook score with momentum as its strongest module and quality as its weakest, but it holds no seat in our index and has not yet drawn a diary mention or quote.
What the diary watches
Whether any of its lead candidates, particularly the pulmonary hypertension programme, move through further trial stages and change the balance across its scored modules.

Roivant Sciences Ltd (ROIV) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 37/100 composite (momentum 82, quality 20, valuation 37) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ROIV, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 3 analyst actions on the wire · latest: price target by Stifel, 2026-09-16

The Street on this name

Analyst actions and the latest print for ROIV from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Stifel — target 51 Target set to $51 (+28.9% to spot) 2026-09-16
  • Price target H.C. Wainwright — target 47 from 41 Target raised to $47 from $41 (+11.8% to spot) 2026-09-08
  • Price target Jefferies — target 52 from 42 Target raised to $52 from $42 (+24.7% to spot) 2026-09-08

3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ROIV on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 320 m USD in FY2026

Dividends and capital return

What ROIV pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2026 320 m USD 1.1% of today's market value
  • Share count −4.3% in FY2026 346 m USD of stock-based compensation in the year
  • Capital returned 320 m USD in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Roivant Sciences Ltd (ROIV)?

Roivant Sciences Ltd trades as ROIV on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is ROIV in a Closelook index?

Not currently — Roivant Sciences Ltd is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Roivant Sciences Ltd's Closelook composite score?

37 out of 100, with momentum 82, quality 20 and valuation 37 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ROIV trade against its moving averages?

Uptrend stack intact: Trades +5.2% vs the 50-day and +29.2% vs the 200-day average, 10.1% below the 52-week high and +163.6% off the 52-week low. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Roivant Sciences Ltd do?

Roivant Sciences discovers, develops and aims to commercialise new medicines, mainly in autoimmune and cardiopulmonary disease. Its pipeline includes antibody and small-molecule candidates for conditions such as pulmonary hypertension, thyroid eye disease and several IgG-mediated autoimmune disorders, alongside lipid-nanoparticle and ligand-conjugate delivery platforms. It is based in London and operates as a clinical-stage biopharmaceutical company rather than a marketer of approved drugs. Closelook's peer group places it with other scored Healthcare names in the US, including argenx, Regeneron, Vertex Pharmaceuticals and BeiGene; the market also often names Alnylam Pharmaceuticals as a comparable clinical-stage biotech.

Where does Roivant Sciences Ltd sit in the AI build-out?

Roivant carries no seat in our index; it belongs to the Healthcare sector of our universe, within the clinical-stage biotechnology sleeve, alongside other US-listed drug developers we track for score comparison rather than for any AI build-out layer. It carries a Closelook score with momentum as its strongest module and quality as its weakest, but it holds no seat in our index and has not yet drawn a diary mention or quote.

Does Roivant Sciences Ltd pay a dividend?

No cash distribution shows in Roivant Sciences Ltd’s price series over the last three years. In fiscal 2026 the company bought back 320 m USD of its own shares. The share count fell 4.3% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Roivant Sciences Ltd recently?

The most recent analyst action on Roivant Sciences Ltd on the Closelook wire is a price target by Stifel on 2026-09-16 (target 51). 3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ROIV, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.